Medicenna Therapeutics stock lags despite MDNA11 and bizaxofusp pipeline milestones

Medicenna Therapeutics stock (ISIN CA5846991016) is trading around CAD 0.37 on the Toronto Stock Exchange as of September 17, 2026, implying a market capitalization of roughly CAD 34.2 million for the clinical-stage immunotherapy company and keeping the shares significantly below their recent peaks per data from a Nasdaq-linked portal on September 17, 2026.

Pipeline updates underpin MDNA11 and bizaxofusp story

Medicenna Therapeutics Corp., which focuses on engineered cytokines and targeted immunotherapies, has highlighted a series of clinical milestones for its MDNA11 and bizaxofusp programs following its recent participation in the H.C. Wainwright Global Investment Conference and other investor forums, according to a conference coverage article on September 17, 2026 from Ad-hoc-news.

According to this coverage citing an investor transcript hosted on Investing.com, Medicenna is advancing the ABILITY-1 trial of MDNA11, which includes plans for an end-of-phase I meeting with the U.S. Food and Drug Administration after an oral presentation of the data to discuss potential phase II registration trials and a possible accelerated approval pathway for one or more tumor cohorts, with interim data from the 80-patient externally funded neoadjuvant study in Italy expected in the fourth quarter of 2026, as reported by Ad-hoc-news.

Cash runway and earnings expectations frame risk profile

The same transcript-based summary notes that Medicenna’s management reiterated a limited cash runway, stating that its current cash balance combined with additional funds anticipated under a sharing agreement provide operational financing into the second quarter of 2024, underscoring that the company remains reliant on future financing or partnership inflows to carry the MDNA11 and bizaxofusp programs beyond that point according to Ad-hoc-news.

In addition, analysts referenced in the same coverage forecast that Medicenna could achieve positive earnings per share of about USD 0.45 in fiscal 2027, which management has pointed to as a potential future inflection point for the business despite the company having remained unprofitable over the trailing twelve months, according to Ad-hoc-news.

Stock trades far below 52-week high

Price data in the same conference-related article indicate that Medicenna Therapeutics stock was recently quoted at about USD 0.29 on September 16, 2026, with the shares more than 80 percent below a 52-week high of USD 1.41 reported for the same period, highlighting how far the stock currently trades from its recent peak according to Ad-hoc-news.

With a market capitalization of around CAD 40 million as of September 16, 2026 based on those USD and CAD figures, Medicenna screens as a small-cap biotechnology name where individual trial readouts, regulatory interactions and financing decisions can rapidly shift sentiment, particularly given that the current share price near USD 0.29 is trading at roughly one-fifth of the 52-week high of USD 1.41, a comparison that underscores how much pipeline optimism has yet to be reflected in the valuation per the same price snapshot from Ad-hoc-news.

Shares remain volatile for biotech investors

For investors, the combination of ambitious clinical goals for MDNA11 and bizaxofusp, a relatively short cash runway into the second quarter of 2024, and the prospect of potential positive EPS of USD 0.45 in fiscal 2027 presents a high-risk, high-variance profile, where future data and funding decisions will likely determine whether Medicenna Therapeutics stock can close the sizable gap between the current trading level of roughly USD 0.29 as of September 16, 2026 and the 52-week high of USD 1.41, using the price comparison highlighted by Ad-hoc-news.

Medicenna Therapeutics stock price and key data

As of the most recent available quote on September 17, 2026 from a Nasdaq-affiliated portal, Medicenna Therapeutics stock closed at approximately CAD 0.37 on its Toronto Stock Exchange listing with a daily move of about minus 7.5 percent compared to the prior close and a market capitalization of around CAD 34.2 million, reinforcing the small-cap nature of the stock for biotechnology-focused investors.

More news and analyses on Medicenna Therapeutics stock